REG - Angle PLC - US and EU patents for innovative CellKeep™ slide

AngleAnnouncement

22/04/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240422:nRSV4192La&default-theme=true

RNS Number : 4192L  Angle PLC  22 April 2024

 For immediate release  22 April 2024

 

 

ANGLE plc ("the Company")

 

US AND EU PATENTS FOR ANGLE'S INNOVATIVE CELLKEEP™ SLIDE

 

Proprietary cell recovery device and method eliminates over 70% of CTC cell
loss from standard microscopy techniques increasing assay sensitivity

 

 

ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company with
innovative circulating tumour cell (CTC) solutions for use in research, drug
development and clinical oncology, is pleased to announce that the European
Patent Office has granted a European Patent for its innovative CellKeep™
slide. A formal communication has also been received from the United States
Patent and Trademark Office indicating that grant of the equivalent US patent
application is imminent.

 

The proprietary CellKeep slide is the result of a three-year development
effort by ANGLE to address CTC loss endemic in standard laboratory microscopy
techniques for the cytological analysis of CTCs.  The result is a new device
and method to attach cells to the slide, which extensive inhouse testing has
demonstrated, eliminates over 70% of CTC loss experienced when using standard
techniques.

 

The Parsortix(®) system efficiently captures CTCs from blood and these remain
intact and viable (live) prior to downstream analysis. When visualising CTCs
by microscopy there is a critical step to transfer CTCs to a slide for
biomarker labelling. In-house testing has shown that standard laboratory
techniques, used worldwide, result in a high rate of cell loss (>50%) and
cause damage to CTCs. Reducing cell loss to a minimum is critical for
subsequent analysis of CTCs as they are present in very low numbers in the
blood.

 

ANGLE has developed the CellKeep slide to reduce cell loss during the transfer
of CTCs to the microscope slide and to protect the morphology of the harvested
cells.  The technique also reduces costs by concentrating the CTCs into a
smaller area on the slide, thereby limiting the quantity of high-cost
antibodies and imaging time required to identify and analyse cells.

 

In analytical studies, CTCs were harvested from duplicate cancer patient blood
samples and deposited on either standard microscope slides or ANGLE's new
CellKeep slides, then processed and stained for CTC biomarkers.  The study
demonstrated that the use of CellKeep slides significantly increased the
identification of CTCs with higher sample positivity rates, and better
preservation of CTC morphology and clusters.

 

The new CellKeep slide is an integral part of ANGLE's Portrait(®)+ CTC
staining kit which is available for customers to identify and enumerate CTCs
harvested using the Parsortix system.

 

ANGLE Chief Executive Officer, Andrew Newland, commented:

"We are delighted to have secured intellectual property rights for our
proprietary CellKeep slide in two major jurisdictions. Following harvesting of
rare CTCs from patient blood samples using the Parsortix system, the CellKeep
slide and associated methodology will significantly improve the capture of
CTCs for microscopy-based biomarker assays and will enhance sensitivity across
ANGLE's assay portfolio. This is a significant technology advancement for the
CTC liquid biopsy field and another step towards enabling biomarker-guided
precision medicine for people with cancer.

 

ANGLE Chief Scientific Officer, Karen Miller commented:

"We are pleased to share our success in securing IP rights for ANGLE's
CellKeep slide which enhances the capture of CTCs on to slides and facilitates
evaluation of cancer cell biomarkers.  This technology is a significant
advancement over current standards for CTCs and has the potential to capture
other cell types from body fluids such as blood, urine or cerebrospinal fluid,
for subsequent analysis.

 

 

For further information:

 

 ANGLE plc                                +44 (0) 1483 343434
 Andrew Newland, Chief Executive

 Ian Griffiths, Finance Director

 Berenberg (NOMAD and Corporate Broker)   +44 (0) 20 3207 7800

 Toby Flaux, Ciaran Walsh, Milo Bonser

 FTI Consulting

 Simon Conway, Ciara Martin               +44 (0) 203 727 1000

 Matthew Ventimiglia (US)                 +1 (212) 850 5624

 

 

The information contained within this announcement is deemed by the Company to
constitute inside information as stipulated under the EU Market Abuse
Regulation (596/2014). Upon the publication of this announcement via a
regulatory information service, this information is considered to be in the
public domain.

 

For Research Use Only. Not for use in diagnostic procedures.

 

For Frequently Used Terms, please see the Company's website on
https://angleplc.com/investor-relations/glossary/
(https://angleplc.com/investor-relations/glossary/)

 

 

Notes for editors

 

About ANGLE plc

 

ANGLE is a world-leading liquid biopsy company with innovative circulating
tumour cell (CTC) solutions for use in research, drug development and clinical
oncology using a simple blood sample. ANGLE's FDA cleared and patent protected
circulating tumour cell (CTC) harvesting technology known as the Parsortix(®)
PC1 System enables complete downstream analysis of the sample including whole
cell imaging and proteomic analysis and full genomic and transcriptomic
molecular analysis.

 

ANGLE's commercial businesses are focusing on diagnostic products and clinical
services. Diagnostic products include the Parsortix(®) system and associated
consumables. The clinical services business is offered through ANGLE's
GCP-compliant laboratory.  Services include custom assay development and
clinical trial sample testing for pharma.

 

Over 90 peer-reviewed publications have demonstrated the performance of the
Parsortix system. For more information, visit www.angleplc.com
(http://www.angleplc.com)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCKZGZDGMVGDZZ